CLINICAL TRIALS PROFILE FOR RUXOLITINIB PHOSPHATE
✉ Email this page to a colleague
All Clinical Trials for ruxolitinib phosphate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00778700 ↗ | A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis | Completed | Incyte Corporation | Phase 2 | 2008-10-01 | The study will be a double-blind, randomized, vehicle-controlled study with application of ruxolitinib phosphate cream or vehicle in patients with stable plaque psoriasis. Application will be QD for 12 weeks without occlusive dressings. There will be 4 treatments of 50 subjects each. |
| NCT00820950 ↗ | A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis | Completed | Incyte Corporation | Phase 2 | 2007-05-01 | The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis. |
| NCT01164163 ↗ | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | Completed | National Cancer Institute (NCI) | Phase 1 | 2010-09-01 | RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease. |
| NCT01164163 ↗ | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | Completed | Children's Oncology Group | Phase 1 | 2010-09-01 | RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease. |
| NCT01431209 ↗ | Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | Completed | Incyte Corporation | Phase 2 | 2011-08-01 | This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ruxolitinib phosphate
Condition Name
Clinical Trial Locations for ruxolitinib phosphate
Trials by Country
Clinical Trial Progress for ruxolitinib phosphate
Clinical Trial Phase
Clinical Trial Sponsors for ruxolitinib phosphate
Sponsor Name
